Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

NCT01651104 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Influenza

Interventions

BIOLOGICAL: Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)

Sponsor

Novartis Vaccines